Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 28.57 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $12.310 million which missed the analyst consensus estimate of $14.342 million by 14.17 percent. This is a 61.99 percent increase over sales of $7.599 million the same period last year.